Veronika Ferenc

Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536

Karoline V. Gleixner, Veronika Ferenc, Barbara Peter et al. · Cancer Research · 2010 · 84 citations

Imatinib Resistance, Hematological Malignancy, Chronic Myeloid Leukemia +13

Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo Classification

Peter Panhofer, Veronika Ferenc, M. Schütz et al. · International Journal of Surgery · 2014 · 70 citations

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

Karl J. Aichberger, Karoline V. Gleixner, Irina Mirkina et al. · Blood · 2009 · 65 citations · Full text

Age, microbiology and prognostic scores help to differentiate between secondary and tertiary peritonitis

Peter Panhofer, Barbara Izay, Markus Riedl et al. · Langenbeck s Archives of Surgery · 2008 · 31 citations

Pediatric Gastroenterology, Pathology, Clinical Gastroenterology +6

Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRα

Christian Baumgärtner, Karoline V. Gleixner, Barbara Peter et al. · Experimental Hematology · 2008 · 24 citations

Tumor Biology, Medicine, Receptor Tyrosine Kinase +8